Bristol-Myers Squibb Company New Data on Investigational Agent Belatacept in Kidney Transplant Recipients to be Presented at 2011 American Transplant Congress

Published: Apr 25, 2011

PRINCETON, N.J.--(BUSINESS WIRE)--New data on belatacept, an investigational selective T cell costimulation blocker being studied for use in renal transplantation by Bristol-Myers Squibb Company (NYSE:BMY), will be presented at the American Transplant Congress April 30 – May 4, 2011 in Philadelphia. In total, 21 abstracts from company-sponsored studies will be presented during the congress, including seven oral presentations related to kidney transplantation. The data being presented highlights the broad clinical program for belatacept, a key compound supporting Bristol-Myers Squibb’s strategy to discover and develop targeted therapies for serious diseases.

Back to news